Bulk transcriptomic analysis on human Tregs

Treg-based therapy is currently limited by the reduced survival of Tregs in vivo, which is largely due to the lack of IL-2 in patients, and yet IL-2 is essential for Treg survival and function. In our study, we generated Tregs expressing a partial agonist form of IL-2 (Tregs-IL2pa) to promote their survival while avoiding the potential excessive signaling associated with wild-type IL-2.The data provided in this project belong to a study aimed at characterizing the transcriptomic profile of Tregs-IL2pa. Specifically, this bulk RNA-seq analysis investigates the transcriptomic profile of these cells in vitro when their sole source of IL-2 is the endogenous production of IL-2.In this study, human Tregs-IL2pa were transduced and then cultured in the absence of exogenous IL-2 for 3 days before sorting and processing for sequencing. This ensured that the observed transcriptomic profile was driven by endogenous IL-2 production, rather than the exogenous IL-2 added during culture. Negative control cells, which only expressed the reporter gene, were also rested in the absence of IL-2, while positive control cells received exogenous IL-2.